Britain and America have established a significant bilateral deal that will guarantee no duties on UK medicine shipments entering the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to boost expenditure on medicines through the public health system. This pledge secures that duties on these vital products will stay at nothing for a period of three years.
This development is in response to previous statements to hike duties on patented drug imports, with potential rates mentioned reaching double the cost.
"This agreement between the United Kingdom bolsters the global environment for new treatments and brings long-overdue equity to U.S.–U.K. pharmaceutical trade," a release said.
Trade Significance
Drugs constitute one of the the United Kingdom's biggest exports to the United States, which is clearly the biggest destination for large UK drugmakers.
Trade data reveal that in the 12 months prior to last September, the UK sold medicines worth billions to the US. This value accounted for 17.4% of British export trade in that timeframe.
"This guarantee protects jobs, stimulates investment and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," a minister stated.
Detailed NHS Changes
The deal includes several notable commitments from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to raise overall public funding on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. Last year, refunds were more than twenty percent.
Industry Background
This agreement follows a ongoing tension between the drug companies and the British authorities over drug pricing and approval rates.
The disagreement were intensified by arguments that American patients were charged several times more for the same drugs than consumers in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been halted or scrapped, while major funding commitments have been pledged toward American operations.
One official stated that the NHS had to invest a greater share on drugs, noting that its spending on drugs had declined as a proportion of its overall budget over the past decade.
